Close Menu

RT-qPCR

Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.

The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.

Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.

The US Department of Health and Human Services (HHS) said that it would use Fluidigm's saliva-based molecular SARS-CoV-2 test as part of a federal surge testing program.

A recent study showed that a method called affine transformation can be used to increase the number of true positive qPCR samples detected.

The NGS-based test is intended for use by lab personnel trained to use Illumina's MiSeq and NextSeq systems.

Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.

Funding for Fluidigm's assay through NIH's RADx program was increased by approximately $22 million for a total contract value of up to about $34 million.

In 2018 Qiagen purchased a 19.9 percent stake in Ann Arbor, Michigan-based NeuMoDx along with the right to acquire the remaining shares.

Reported as "nucleic acid amplification test-detectable" units per milliliter, the limits of detection of more than 50 commercial tests differed by 10,000-fold.

Pages

The Wall Street Journal reports on gaps in COVID-19 testing affecting less affluent urban areas and rural locations.

According to NBC News, new SARS-CoV-2 variants are making it harder for researchers to model the course of the pandemic.

The New York Times reports that experts say President Joe Biden's goal of vaccinating 1 million people a day in the US in the next 100 days is too low a bar.

In Science this week: single-cell lineage tracing technique applied to study lung cancer metastasis, and more.